-
PR
Presented at the AMED Seeds Acceleration Pitch and JHVS Venture Awards 2024 at the Japan Healthcare Venture Summit (JHVS) 2024.
-
PR
Professor Kenji Osafune, Chief Scientific Advisor gave lectures in Taiwan
-
PR
Rege Nephro Co., Ltd. Successfully Completes Series B Funding to Accelerate Kidney Disease Therapy Trials
-
MEDIA
Upcoming Feature on NHK World JAPAN Science View: Freeing Patients from Dialysis! -Dr. Kenji OSAFUNE’s Challenge
-
PR
Rege Nephro’s Chief Executive Officer gave a lecture at Regenerative Medicine Expo[Tokyo].
-
Presented at the AMED Seeds Acceleration Pitch and JHVS Venture Awards 2024 at the Japan Healthcare Venture Summit (JHVS) 2024.
-
Professor Kenji Osafune, Chief Scientific Advisor gave lectures in Taiwan
-
Rege Nephro Co., Ltd. Successfully Completes Series B Funding to Accelerate Kidney Disease Therapy Trials
-
Rege Nephro’s Chief Executive Officer gave a lecture at Regenerative Medicine Expo[Tokyo].
-
Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD
-
Upcoming Feature on NHK World JAPAN Science View: Freeing Patients from Dialysis! -Dr. Kenji OSAFUNE’s Challenge
-
Our business was introduced in Science Japan, an online magazine published by JST.
-
An article about Toshihiro Ishikiriyama, our president, was published in AnswersNews, serial column: Venture Round Visit Report.
-
Featured in Nikkei newspaper, its electronic version, Asahi Shimbun DIGITAL and many other media.
-
Published in the Nikkei newspaper and the electronic version.